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Efﬁcient transduction of pigtailed macaque hematopoietic repopulating cells with
HIV-based lentiviral vectors
Grant D. Trobridge,1,2 Brian C. Beard,1 Christina Gooch,1 Martin Wohlfahrt,1 Philip Olsen,1 James Fletcher,2 Punam Malik,3
and Hans-Peter Kiem1,2
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; 2Department of Medicine, University of Washington School of Medicine,
Seattle; and 3Division of Experimental Hematology and Division of Hematology Oncology, Cincinnati Children’s Hospital Medical Center, OH
Lentiviral vectors are attractive for hemato-
poietic stem cell (HSC) gene therapy be-
causetheydonotrequiremitosisfornuclear
entry, they efﬁciently transduce hematopoi-
etic repopulating cells, and self-inactivating
(SIN) designs can be produced at high titer.
Experiments to evaluate HIV-derived lentivi-
ral vectors in nonhuman primates prior to
clinical trials have been hampered by low
transduction frequencies due in part to host
restriction by TRIM5. We have established
conditions for efﬁcient transduction of pig-
tailed macaque (Macaca nemestrina) long-
term repopulating cells using VSV-G–
pseudotyped HIV-based lentiviral vectors.
Stable, long-term, high-level gene marking
was observed in 3 macaques using rela-
tively low MOIs (5-10) in a 48-hour ex vivo
transduction protocol. All animals studied
had rapid neutrophil engraftment with a me-
dian of 10.3 days to a count greater than
0.5  109/L (500/L). Expression was de-
tected in all lineages, with long-term mark-
ing levels in granulocytes at approximately
20% to 30%, and in lymphocytes at approxi-
mately 12% to 23%. All animals had poly-
clonal engraftment as determined by analy-
sis of vector integration sites. These data
suggest that lentiviral vectors should be
highly effective for HSC gene therapy, par-
ticularly for diseases in which maintaining
the engraftment potential of stem cells us-
ing short-term ex vivo transduction proto-
cols is critical. (Blood. 2008;111:5537-5543)
© 2008 by TheAmerican Society of Hematology
Introduction
Nonhuman primate models have been invaluable for developing
hematopoietic gene therapy strategies for humans because gene
transfer and stem cell clonality closely simulate that seen in
patients. Gene therapy has now cured several hematopoietic
diseases,asevidencedbysuccessesforimmunodeﬁcienciesinclud-
ing X-linked severe combined immunodeﬁciency (SCID-X1),
adenosine deaminase (ADA) deﬁciency, and more recently chronic
granulomatous disease (CGD). However, the risk of malignancy
from vector integration is signiﬁcant, as evidenced in the French
SCID-X1 trial where 4 of 10 patients have developed leukemia that
can be directly attributed to vector-mediated oncogene activation.1
These ﬁndings have highlighted the importance of developing safer
vector systems and developing animal models to evaluate vector
integration and genotoxicity.
HIV-based lentiviral vectors are now being used in human trials
because they offer several advantages for hematopoietic stem cell
(HSC) gene therapy. Lentiviral vectors can enter the nucleus
independent of mitosis, and are able to efﬁciently deliver complex
transgenes such as globin genes that are not delivered efﬁciently by
gammaretroviral vectors.2 Lentiviral self-inactivating (SIN) vec-
tors have deletions of enhancer and promoter sequences in the long
terminal repeats (LTRs) designed to reduce the potential for
transactivation of host genes and can be produced at high titer.
While murine leukemia virus (MLV)–based gammaretroviral vec-
torsfavorintegrationintoregionsnearpromoters,3humanimmuno-
deﬁciency virus 1 (HIV1)–based lentiviral vectors integrate prefer-
entially within genes.4 In addition, in canine and primate long-term
repopulating cells, gammaretroviral vectors were found more
frequently near (within 5000 bp) proto-oncogene start sites than
HIV-based lentiviral vectors.5,6Acomparison of the genotoxicity of
SIN lentiviral vectors to gammaretroviral vectors with LTR-driven
transgenes similar to the ones used in the SCID-X1 trial suggests
that SIN lentiviral vectors may be safer, at least in a murine model.7
We have previously shown that HIV-based lentiviral vectors can
mediate gene transfer to long-term repopulating cells in the canine
model,8 but gene transfer into primate models including the rhesus
macaque9,10 and the baboon has been inefﬁcient,11 likely due to host
restriction factors including TRIM5.12 The rhesus macaque
TRIM5 potently restricts HIV-1 replication by accelerating capsid
uncoating after cell entry.13 Restriction has also been seen with
SIV-based vectors in human hematopoietic cells.14
We found that pigtailed macaque (Macaca nemestrina) CD34
cells are highly permissive for transduction by HIV-1–derived
vectors and describe efﬁcient transduction of pigtailed macaque
long-term repopulating cells using HIV-based lentiviral vectors at
relatively low MOIs. This nonhuman primate model will be very
useful for preclinical studies to evaluate the safety and efﬁcacy of
HIV-1–based vectors proposed for clinical studies.
Methods
Animal care
Healthy juvenile baboons (Papio cynocephalus anubis) and pigtailed
macaques (Macaca nemestrina) were housed at the University of Washing-
ton National Primate Research Center under conditions approved by the
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protocols were approved by the Institutional Review Board and the
Institutional Animal Care and Use Committee. Prior to hematopoietic cell
collection, animals were administered recombinant human granulocyte
colony-stimulating factor (rhG-CSF, 100 g/kg), and also given recombi-
nant human stem cell factor (rhSCF, 50 g/kg) daily as subcutaneous
injections for 5 days. On day 5, bone marrow was harvested from the
humeri and/or femora. In preparation for transplantation, all animals
received myeloablative total-body irradiation. Twenty-four hours
after transplantation, the animals were started on intravenous G-CSF at
100 g/kg daily until the animals attained stable neutrophil engraftment
with an absolute neutrophil count of greater than 0.5  109/L (500/L).
Standard supportive care, including blood product transfusions, ﬂuid and
electrolyte management, and antibiotics, was administered as needed.
Hematopoietic recovery was monitored by daily complete blood counts.
Retroviral vectors
The HIV vectors were SIN pRRL15 or pWPT-GFP (provided by Didier
Trono, Lausanne, Switzerland) vector backbones containing a central
polypurine tract, and a woodchuck posttranscriptional regulatory element.
The HIV-based vector internal promoters were either an internal elongation
factor 1 promoter for animal J02043, or both a spleen-focus forming virus
SFFV expressing a P140K methylguanine methyltransferase (MGMT)
transgene and a phosphoglycerate kinase (PGK) promoter driving expres-
sion of enhanced green ﬂuorescent protein (EGFP) for animals J02370 and
T04228. For the in vitro studies, the lentiviral vectors expressed EGFPfrom
the PGK promoter. HIV-based vectors were pseudotyped with VSV-G
envelope and produced by transient transfection of 293T cells and
concentrated 100-fold as previously described.8
Comparison of HIV vector transduction in human, macaque,
and baboon cells in vitro
Human HT1080 ﬁbrosarcoma cells were cultured in Dulbecco modiﬁed
Eagle medium with 10% fetal bovine serum and with 100 U/mL penicillin
and 100 g/mL streptomycin. Macaque and baboon CD34 cells were
collected from rhG-CSF and stem cell factor (SCF)–primed bone marrow,
and human CD34 cells were collected from G-CSF–mobilized human
volunteers. For CD34 transductions, cells were cryopreserved and then
thawed and immediately exposed to a lenti vector at an MOI of 5 or 50 in
Iscove modiﬁed Dulbecco medium (IMDM) with 10% FBS with 100 U/mL
penicillin and 100 g/mL streptomycin, supplemented with 100 ng/mL
recombinant human stem cell factor (rhSCF), 100 ng/mL recombinant
human Flt-3 ligand (rhuFlt3-L), 100 ng/mL interleukin-3 (IL-3), 100 ng/mL
IL-6, 100 ng/mL thrombopoietin (TPO), and 100 ng/mL G-CSF in
CH-296–coated tissue culture plates.After 18 hours, the cells were replated
in growth media plus cytokines, and percentage of cells expressing EGFP
was determined by ﬂow cytometry at day 3 or day 5 after transduction.
Primate CD34 isolation, retrovirus transduction, and
transplantation
CD34 cell enrichment was performed using the 12.8 IgM anti-CD34
antibody and MACS IgM microbeads (Miltenyi Biotec, Auburn, CA)
according to the manufacturer’s instructions and as described previ-
ously.16,17 CD34-enriched primate cells were cultured in IMDM with 10%
FBS with 100 U/mLpenicillin and 100 g/mLstreptomycin, supplemented
with 100 ng/mL rhSCF, 100 ng/mL rhuFlt3-L, 100 ng/mL interleukin-3
(IL-3), 100 ng/mL IL-6, 100 ng/mL TPO, and 100 ng/mL G-CSF for 15 to
18 hours before transduction. For transduction, cells were supplemented
with the same cytokine combination in ﬂasks previously coated with the
CH-296 fragment of ﬁbronectin (Takara, Shiga, Japan). The transduction
medium was also supplemented with 4 g/mL protamine sulfate. For
animals J02043 and T04228, 1 g/mL cyclosporine was also added. The
cells were exposed to an initial dose of vector for 6.5 to 8 hours and then
exposed to second dose of vector overnight for 17 to 18 hours. Following
transduction, cells were infused into recipients after myeloablative total
body irradiation (TBI) conditioning. Animal J02043 received a myeloabla-
tive dose of 1020 cGy TBI in 2 doses of 510 cGy, and animals J02370 and
T04228 received 800 cGy in 4 doses of 200 cGy from a single source linear
X-ray accelerator (Linac Systems, Lakewood, NJ) at 7 cGy/minute. After
infusion of autologous gene-modiﬁed cells, the animals received recombi-
nant G-CSF at 100 g/kg daily until the animals maintained an absolute
neutrophil count (ANC) of greater than 0.5  109/L (500/L). The animals
also received standard supportive care including intravenous hydration and
broad spectrum antibiotics (ceftazadime, vancomycin, gentamicin), an
antiviral agent (acyclovir), an antifungal agent (ﬂuconozol), and transfu-
sions with irradiated pigtailed macaque whole blood for treatment of
posttransplantation thrombocytopenia.
CFU assay
Transduced and mock-transduced CD34-enriched cells were cultured in a
double-layer agar culture system as previously described.6,18 Colonies were
enumerated and evaluated for GFP expression on day 14 of culture using
ﬂuorescence microscopy.
Retrovirus-speciﬁc LAM-PCR
Retroviral integration site analysis by linear ampliﬁcation–mediated poly-
merase chain reaction (LAM-PCR) was performed on primate DNA
isolated from peripheral blood leukocytes and has been described in detail
elsewhere.5,19,20 Brieﬂy, initial linear ampliﬁcation PCR was performed
with biotin-tagged LTR-speciﬁc primers and after further processing,
samples were digested to create compatible genomic restriction site
overhangs with either Tsp509I or MspI restriction enzymes (New England
Biolabs, Ipswich, MA). Internal vector amplicons were eliminated with
retrovirus-speciﬁc restriction enzyme digestion, and an enzyme-speciﬁc
linker cassette was ligated to the restriction enzyme site of the genomic
DNAbound to beads creating binding sites for reverse primers. Nested PCR
was carried out and the PCR reactions were separated on an acrylamide gel
and stained with ethidium bromide to visualize PCR products.
Flow cytometric analysis of macaque hematopoietic cells
Leukocytes isolated by ammonium chloride red cell lysis from heparinized
peripheral blood and bone marrow samples drawn at multiple time points
after transplantation were analyzed for EGFP expression on a FACSVan-
tage or FACSCalibur (Becton Dickinson, San Jose, CA). Transgene
expression in granulocyte, monocyte, and lymphocyte populations was
determined by gating based on either forward and right-angle light scatter
characteristics or expression of lineage-speciﬁc CD markers. The antibod-
ies used for lineage-speciﬁc markers included CD3 (clone SP34-2), CD13
(clone L138), CD20 (clone L27), and CD34 (clone 563). All antibodies
were supplied by Becton Dickinson (Franklin Lakes, NJ) and conjugated to
phycoerythrin. Red cells and platelets from whole blood diluted in
phosphate-buffered saline were delineated by forward and right-angle light
scatter properties and assessed for EGFPexpression.
DNA analysis of gene marking
Relative marking levels were analyzed with the TaqMan 5 nuclease
quantitative real-time polymerase chain reaction (PCR) assay.21 We ampli-
ﬁed 300 ng DNA in at least duplicate with an EGFP-speciﬁc primer/probe
combination (5-CTG CAC CAC CGG CAA-3 and 5-GTA GCG GCT
GAA GCA CTG-3; probe, 5-FAM-CCA CCC TGA CCT ACG GCG
TG-TAMRA-3) (Synthegen, Houston, TX) or a primer/probe combination
speciﬁc to the lentiviral cis-acting region (5-TGAAAG CGAAAG GGA
AAC CA-3,5 -CCG TGC GCG CTT CAG-3; probe, 5-FAM-AGC TCT
CTC GAC GCA GGA CTC GGC-TAMRA-3). Standards consisted of
dilutions of DNA extracted from a cell line containing a single lentiviral
vector provirus. Negative controls consisted of DNA extracted from
peripheral blood mononuclear cells (PBMCs) obtained before transplanta-
tion from control animals or water. A monkey-speciﬁc betaglobin primer/
probecombinationwasusedtoadjustforequalloadingofDNAperreaction
(5-TGG CTA ATG CCC TGG CCC ACA AGT A-3; primer sequences
BG73F, 5-CCT ATC AGA AAG TGG TGG CTG G-3 and BG149R,
5-TTG GAC AGC AAG AAA GTG AGC TT-3). Reactions were run by
5538 TROBRIDGE et al BLOOD, 15 JUNE 2008 VOLUME 111, NUMBER 12
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From the ABI master mix (Applied Biosystems, Branchburg, NJ) on the ABI
Prism 7700 sequence detection system (Applied Biosystems) under the
following thermal cycling conditions: 50°C for 2 minutes and 95°C for
10 minutes, then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.
For Southern blot analysis,22 peripheral blood DNA was digested with
the restriction enzymes AvaI and XmnI (New England Biolabs) that cleave
within the lentiviral vector to produce an internal 1083-bp fragment from
the cis-acting region. DNAfrom the single copy control cell line was mixed
at different ratios with DNA from a cell line with no lentiviral vector
provirus to generate copy number standards. Following digestion, approxi-
mately 10 g DNA was electrophoresed, transferred to a Hybond-N
membrane (GE Healthcare, Waukesha, WI), and hybridized using Quick-
Hyb hybridization solution (Stratagene, La Jolla, CA) following manufac-
turers’ recommendations. The 1083-bp lentiviral vector cis-acting region
probe was generated by nested PCR ampliﬁcation from 10 pg lentiviral
vector plasmid DNA, then digested with XmnI and AvaI and gel-puriﬁed.
Detection of replication-competent virus
Serum of all 3 animals was tested for the presence of recombinant
replication-competent lentiviral vectors by the p24 Antigen Assay (Beck-
man Coulter, Miami, FL) according to the manufacturer’s recommenda-
tions. The p24 antigen was not detectable, indicating the absence of
helper-virus production.
Results
Efﬁcient transduction of pigtailed macaque cells in vitro
We had previously observed persistent but low-level transduction
of baboon repopulating cells (Papio cynocephalus anubis) using
HIV-1–derived lentiviral vectors,11 likely due to restriction medi-
ated by TRIM5.12 However, pigtailed macaques are permissive
for HIV-1 replication23 and thus may not have as potent a
TRIM5-mediated restriction to HIV-1 infection as observed in
other primate species. To determine the relative susceptibility of
pigtailed macaque leukocytes to transduction by HIV-based vec-
tors, we compared the efﬁciency of transduction of human,
pigtailed macaque, rhesus macaque, and baboon CD34 cells using
HIV vectors pseudotyped with vesicular stomatitis virus glycopro-
tein (VSV-G) that expressed enhanced green ﬂuorescent protein
(EGFP). Transduction of CD34 cells was performed in vitro at
2 multiplicities of infection (Figure 1).As expected, compared with
human cells, the baboon and rhesus cells were relatively refractory
to transduction with HIV-based vectors. At a high MOI, the rhesus
CD34 cells were transduced efﬁciently; however, as would be
expected at the low MOI, the rhesus cells were refractory to
transduction with approximately 10% expressing EGFP. Con-
versely, at the low MOI both the human and pigtailed macaque
CD34 cells were efﬁciently transduced with greater than 50% of
cells expressing EGFP. It has previously been reported that
postentry restriction to HIV infection in monkey cells can be
saturated by noninfectious capsids,24-26 which likely explains the
ability of the HIV-1 vector to efﬁciently transduce both pigtailed
and rhesus macaque cells at high MOI but not the rhesus macaque
cells efﬁciently at a low MOI.
Engraftment after transplantation of lenti vector
transduced cells
We performed a series of 3 transplantations in pigtailed macaques
using HIV-based vectors. In the 3 animals, a stable absolute
neutrophil count (ANC) greater than 0.5  109/L (500/L) was
reached by either day 10 or day 11 (Table 1). A platelet count
greater than 20  109/L 20 000/L was reached at an average of
29 days. Figure 2 displays the ANC and platelet counts after
transplantation for all 3 animals in this study. Engraftment was
slightly less rapid, but similar to engraftment of rhesus macaques
that received CD34 cells transduced with SIV-based vectors
pseudotyped with an amphotropic envelope in which the mean time
to ANC greater than 0.5  109/L (500/L) was 7.3 days.14 These
data show that monkey CD34 cells exposed to lentiviral vectors
pseudotyped with VSV-G at low MOIs5-10 retain robust capacity
for engraftment.
Gene transfer efﬁciency before transplantation
Transduction efﬁciency before transplantation was assessed by
ﬂow cytometric determination of EGFP-positive CD34-enriched
cells for vectors that encoded a ﬂuorescent marker (monkeys
J02370 and T04228) or by performing real-time PCR for vector
sequences (J02043). Gene transfer levels were high, especially
given the relatively low MOI.5-10 Table 1 summarizes the results of
the pretransplantation analysis of macaque CD34 cells.
Figure 1. Relative transduction efﬁciency of human, pigtailed macaque, rhe-
sus, and baboon CD34 cells with HIV-based vectors. Cryopreserved CD34
cells were thawed and transduced with a lentiviral EGFPvector and the percentage of
EGFP-expressing cells was determined 5 days after vector exposure. The mean and
standard error from 3 experiments is shown.
Table 1. Lentiviral transduction and engraftment of pigtailed macaque CD34 cells
Monkey*
No. of CD34-enriched
cells/kg 106 before
culture
Purity of CD34-
enriched cells, %
No. of infused
cells/kg 106 MOI†
Preinfusion
transduction
efﬁciency,‡
Days to ANC
greater than
0.5  109/L
(500/L)
Days to platelet
count greater
than 2  1010/L
(20 000/L)
J02043 (4.0 kg) 20 82 4.6 10 4.3 (PCR) 11 27
J02370 (4.6 kg) 30 97 11.7 10 30% (EGFP) 10 35
T04228 (3.6 kg) 40 85 10.7 5 17.5% (EGFP) 10 25
For all monkeys, the source of CD34 cells was bone marrow.
*Monkey and weight at time of transplantation in parentheses.
†Multiplicity of infection based on titer determined by transduction of HT1080 cells.
‡Average proviral copy number in day-5 liquid cultures by real-time PCR (J02043) or percentage of ﬂuorescence-positive cells assessed by ﬂow cytometry for EGFP in
liquid cultures on day 11 after transduction for vectors that contained EGFP (monkeys J02370 and T04228).
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repopulating cells
Monkeys J02370 andT04228 received a transplant of cells exposed
to an EGFP-expressing vector, so the transduction efﬁciency of
hematopoietic repopulating cells after transplantation could be
accurately measured by ﬂow cytometric detection of EGFP in
peripheral blood (PB) cells (Figure 2C,D). We observed stable
long-term ( 450 and  441 days) transgene expression with high
marking levels in both granulocytes and lymphocytes, respectively.
Long-term marking (more than 90 days after transplantation) rose
to as high as 36% and 50% in T04228 and J02370, respectively, in
short-lived granulocytes, and was typically between 20% and 35%,
demonstrating efﬁcient gene transfer to primitive repopulating
cells. Marking in PB lymphocytes rose to as high as 23% and 17%
in J02370 and T04228, respectively. The slow rise of transgene-
expressing lymphocytes to a plateau in both animals suggests gene
transfer to primitive repopulating cells with typical lymphocyte
engraftment kinetics. The level of transgene-expressing cells was
very stable over time, and marking was comparable between
myeloid and lymphoid cells at later time points.
Gene transfer rates after transplantation were also determined at
several time points by real-time PCR for all 3 monkeys (Figure 3A)
using primers speciﬁc for the lentiviral cis-acting region. The
average proviral copy number was determined using a control cell
line that contains a single lentiviral vector provirus. The real-time
PCR analysis showed that monkey J02043 that received cells
transduced with a vector that did not encode a ﬂuorescent marker
also had very high marking with an average proviral copy number
of 1.3 that varied between 0.9 and 1.4. The EGFP-expressing
monkey J02370 had an average proviral copy number of 0.6 that
varied between 0.5 and 0.75, and monkey T04428 had an average
proviral copy number of 0.4 that varied between 0.2 and 0.6. In
monkeys J02370 and T04228, these data conﬁrm the high-level
marking assessed using the EGFPtransgene and correlate well with
the relative marking observed using transgene expression. Given
that approximately 25% of the PB leukocytes expressed transgene
in J02370 and the average proviral copy number was approxi-
mately 0.6, the average copy number in repopulating cells that
Figure 2. Engraftment and transgene expression levels in peripheral blood
cells of monkeys that received lentivirally transduced stem cells from bone
marrow using a 48-hour transduction protocol. Displayed for all 3 monkeys
that underwent transplantation are the absolute neutrophil counts (A) and platelet
counts (B) after transplantation. The solid line marks the interpolated time course of
average cell numbers. The percentages of EGFP-expressing leukocytes detected by
ﬂow cytometry are shown for monkeys J02370 (C) and T04228 (D).
Figure 3. Gene marking levels in peripheral blood cells of monkeys that
received HIV-based lentiviral transduced marrow stem cells. (A) The vector
provirus genomes in PB from monkeys J02043, J02370, and T04228 were deter-
mined by Taqman PCR relative to a control cell line with a single integrated lentiviral
vector to determine the average proviral vector copy number. The average copy
number from all dates is indicated in parentheses. (B) Southern blot analysis conﬁrms
high-level marking in all 3 monkeys. Vertical lines indicate repositioned gel lanes.
5540 TROBRIDGE et al BLOOD, 15 JUNE 2008 VOLUME 111, NUMBER 12
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From contain at least one vector provirus can be estimated to be
approximately 2.4 if there was no silencing of transgene expres-
sion, or lower if there was some level of silencing. For monkey
T04228, approximately 20% of PB leukocytes expressed the EGFP
transgene, which would result in an upper limit of 2 for the average
proviral copy number in repopulating cells that contain at least one
vector provirus. LAM-PCR analysis of CFUs suggested that most
colonies had more than one integrant (data not shown), indicating
that there was very little silencing of transgene expression in this
animal. High-level marking was conﬁrmed by Southern blot
analysis for all 3 animals, and the relative levels between monkeys
correlated well with real-time PCR and EGFP expression data
(Figure 3B). However, the marking levels were approximately
2-fold lower than observed by ﬂow cytometry or real-time PCR.
This difference might be explained in part by differences in loading
of the DNA prior to Southern blot analysis (data not shown). It
should be noted that all 3 monkeys contained a mutant MGMT
gene for in vivo selection, but the marking data presented here were
obtained without any in vivo selection.
Analysis of gene expression in hematopoietic lineages
To assess gene expression in different hematopoietic lineages, PB
cells were labeled with antibodies against granulocytes (CD13),
T lymphocytes (CD3), and B lymphocytes (CD20), and analyzed
by ﬂow cytometry. We also determined the marking levels in
BM-derived CD34 cells. Figure 4A shows representative results
obtained in the 2 monkeys that received the EGFPvectors at 67 and
174 days (J02370) and 116 and 441 days (T04228) after transplan-
tation. Sustained EGFP expression could be detected in all subsets
examined, and ﬂow cytometric proﬁles are shown in Figure 4B. In
both monkeys, we were also able to detect ﬂuorescence-positive
platelets and ﬂuorescence-positive erythrocytes (Figure 4C,D).
Since EGFP ﬂuorescence intensity in these cell populations is
signiﬁcantly lower than in white blood cells, these data likely
underestimate marking in erythropoietic progenitors. Both of these
cell populations are enucleated, and are therefore transcriptionally
inactive, so the EGFP protein half-life largely dictates the level of
expression. We have monitored these animals by performing
complete blood counts to monitor the potential development of
myeloproliferation, lymphoproliferation, or leukemia. To date,
there has been no evidence of malignancy and all 3 animals remain
healthy.
Clonality of transduced macaque repopulating cells
LAM-PCR was performed on the PB from all 3 animals to evaluate
the clonality of the engrafted cells.All 3 monkeys engrafted with a
polyclonal set of repopulating cells as evidenced by multiple
LAM-PCR fragment sizes (Figure 5).We have identiﬁed more than
235 unique integration sites in these monkeys, and a detailed
analysis of these integration sites has been published elsewhere.6
Animals J02370 and J02043 have since been moved to another
study, but all monkeys are currently alive and well at 463 (T04228),
698 (J02370), and 981 days (J02043) after transplantation.
Discussion
We evaluated the ability of HIV-derived viral vectors pseudotyped
with VSV-G to transduce HSCs in a clinically relevant monkey
model.Aprevious study had shown that pigtailed macaque cells are
permissive for HIV infection,23 suggesting that they may have less
potent restriction mechanisms for transduction by HIVvectors than
other primate species. We show here for the ﬁrst time that pigtailed
macaque long-term hematopoietic repopulating cells can be efﬁ-
ciently transduced by HIV-1–derived lentiviral vectors. Transduc-
tion levels were considerably higher than seen with baboon or
rhesus CD34 cells. Pigtailed macaques and rhesus macaques have
different amino acids in the TRIM5 SPRY domain27 that confer
species-speciﬁc capsid restriction.28 Our ﬁndings are consistent
with a recent report that identiﬁed truncated forms of TRIM5 in
M nemestrina that do not restrict HIV-1 infection.29These defective
M nemestrina TRIM5 isoforms likely explain why we were able
to efﬁciently transduce pigtailed macaque cells at low MOIs using
the wild-type HIV-1 capsid, which is potently restricted by rhesus
Figure 4. Flow cytometric analysis of transgene-expressing cells in peripheral
blood subpopulations and BM CD34 cells. (A) The percentage of transgene-
positive cells in different leukocyte subpopulations in the peripheral blood of monkeys
that received an EGFP-expressing vector at days 67 and 174 (J02370), or days 116
and 441 (T04228) after transplantation. In these monkeys, EGFP-expressing cells
were found in all lineages examined. (B) Flow cytometry data for EGFP expression in
different lineages from animal T04228 at day 441. Each lineage was identiﬁed with a
phycoerythrin (PE)–labeled antibody. The percentages shown are for the total
number of EGFP- and lineage-positive cells over the total number of lineage positive
cells. (C) Gating on red blood cells (RBCs) and platelets (PLTs) was based on scatter
characteristics (S-SC is side scatter and F-SC is forward scatter). (D) EGFP-
expressing red blood cells (top panels) and platelets (bottom panels) are plotted with
side scatter for a control animal and for animal J02370. Because of the overlapping
positive and negative populations due to low ﬂuorescence intensity, especially in red
blood cells, the percentages of marked cells (5.6% in red blood cells, 6.7% in
platelets) likely underestimate the actual percentage of EGFP-expressing cells.
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TRIM5 also likely explain the higher marking we observed here
relative to previous studies using HIV-based vectors in the rhesus
macaque model where long-term marking was typically lower than
3% with one animal having marking levels of approximately 10%
and 2% in granulocytes and lymphocytes, respectively.9,10
In 3 monkeys that received autologous CD34 cells transduced
with VSV-G–pseudotyped HIV vectors, we observed stable, high-
level gene transfer into long-term hematopoietic repopulating cells.
Long-term marking was as high as 50% into short-lived PB
granulocytes, demonstrating efﬁcient transduction of primitive
cells.Approximately 20% to 35% of granulocytes and 12% to 23%
of PB lymphocytes expressed the EGFP transgene long term as
determined by ﬂow cytometry. This is a remarkable level consider-
ing the relatively short transduction period (48 hours) and the low
MOIs5-10 used. Engraftment was relatively rapid with a mean of
10.3 days to an ANC greater than 0.5  109/L (500/L) and was
stable over time in both monkeys in which the EGFP ﬂuorescent
marker could be followed by ﬂow cytometry of PB leukocytes. In
all 3 monkeys, real-time PCR yielded consistently high level
marking that could be readily detected by Southern blot analysis.
The most accepted assay for the transduction of stem cells is the
ability to deliver genes to large animal repopulating cells that
differentiate into all blood lineages and persist long term. We were
able to track marking in the 3 monkeys for 5, 15, and 15 months,
and for animals J02370 and T04228, EGFP-expressing cells were
detected in all hematopoietic lineages including red blood cells and
platelets. These data strongly suggest that long-term, multipotent
repopulating cells were transduced with the VSV-G–pseudotyped
lentiviral vectors. A previous study showed efﬁcient gene transfer
to rhesus macaque repopulating cells using simian immunodeﬁ-
ciency virus vectors pseudotyped with an amphotropic receptor14 at
similar levels to what we observed here. However, in the rhesus
study the SIV-derived vectors did not transduce human CD34
cells as efﬁciently as rhesus macaque CD34 cells. We have used
HIV-1–based vectors that have a capsid that is not sensitive to
human TRIM5 so the marking levels we have observed in the
pigtailed macaque model using HIV-derived vectors should trans-
late well to clinical studies.
Gene transfer levels detected in PB were similar to those
determined in bone marrow leukocytes (Figure 4A). These data
suggest that there is no block in differentiation or elimination of
mature gene-modiﬁed cells. Comparison of the number of gene-
expressing cells with the marking determined by real-time PCR
showed that signiﬁcant silencing did not occur over time. The
clonality as assessed by the number of bands identiﬁed by
LAM-PCR and the number of unique integrations sites that could
be identiﬁed from sequencing these bands was higher than historic
controls transduced with gammaretroviral vectors.6,18 Thus, trans-
duction with HIV-based lentiviral vectors leads to engraftment of a
large number of repopulating clones. These data, taken together
with the rapid engraftment, show that repopulating cells retain
robust engraftment capability after exposure to HIV vectors
pseudotyped with VSV-G in a 48-hour ex vivo transduction
protocol. In a previous study where VSV-G–pseudotyped gamma-
retroviral vectors were compared with gammaretroviral vectors
pseudotyped with the amphotropic receptor, marking levels were
less than 1% for both pseudotypes, but there was no evidence that
the concentrated VSV-G–pseudotyped vectors were more toxic
than unconcentrated vectors with the amphotropic receptor.30
Given that lentiviral vectors are able to transduce cells indepen-
dently of mitosis and that either amphotropic14 or VSV-G–
pseudotyped lentiviral vectors (our data) can lead to long-term,
polyclonal repopulation in primates with marking levels in the
range of 10% to 30%, it is unclear whether receptor levels,
quiescence, or other factors limit even more efﬁcient transduction.
If the limiting factor is host receptor levels, a cocktail of HIV
vectors with different envelope pseudotypes might further increase
gene transfer to HSCs.
The risk of leukemia as a result of vector integration remains a
signiﬁcant concern for HSC gene therapy. Clinical studies have
shown that activation of host genes by integrated gammaretroviral
vector proviruses can lead to clonal expansion of repopulating
clones31 or leukemia.32 In our study, we used SIN HIV vectors that
expressed transgenes from internal promoters. A murine study has
suggested that the genotoxicity associated with SIN HIV vectors is
lower than for gammaretroviral vectors that express transgenes
from the LTR.7 To date, we have not observed clonal expansion or
malignant transformation in these monkeys, and all monkeys
remain in good health. However, the leukemias observed in the
French trial took approximately 3 years to develop so long-term
follow-up for these monkeys will be important to further evaluate
the safety of these SIN lentiviral vectors. The risk of malignancy as
a result of insertional mutagenesis increases with the number of
proviral copies, so limiting the number of integrations while still
maintaining transgene expression is important for HSC gene
therapy. We found no evidence of signiﬁcant silencing, and
comparing the real-time PCR data to the EGFP transgene expres-
sion data in PB suggests that the average proviral copy number in
transduced long-term repopulating cells is approximately 2. Thus
in the macaque model, SIN HIV vectors used at MOIs of 5 to 10
resulted in relatively low vector provirus copy numbers and
provided robust transgene expression without signiﬁcant silencing.
In conclusion, we report efﬁcient and reproducible transduction
of long-term, multipotent primate repopulating cells in a short
overnight transduction protocol using HIV-based lentiviral vectors.
These data show that using our described protocol, clinically
relevant marking can be obtained in a primate model. Our data also
show that pigtailed macaques are an excellent preclinical model for
HSC gene therapy using HIV-based vectors. The relatively short
transduction protocol described here should be particularly impor-
tant for diseases such as Fanconi anemia where maintenance of
stem cells during ex vivo transduction may be an obstacle to
Figure 5. Polyclonal repopulation with transduced hematopoietic cells. Periph-
eral blood samples were analyzed by LAM-PCR revealing polyclonal repopulation of
all 3 monkeys.An ethidium bromide–stained acrylamide gel of LAM-PCR products is
shown; L, 50 bp standard. In lanes labeled M, DNA samples were digested with the
restriction enzyme MspI, and in lanes labeled T, DNA samples were digested with
Tsp509I restriction enzymes that have compatible sticky ends. The day after
transplantation on which the PB samples were collected is listed below (d153 is day
153 after transplantation). The vertical line indicates a repositioned gel lane.
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served in all 3 animals also suggests that VSV-G–pseudotyped
HIV-based vectors may be effective for transplantations using less
toxic nonmyeloablative preparative regimens, where maintenance
of stem cell potential during ex vivo culture will be critical.
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